Related Experiment Video

Updated: Aug 17, 2026

Zebrafish Model of Neuroblastoma Metastasis
05:20

Zebrafish Model of Neuroblastoma Metastasis

Published on: March 14, 2021

MDM2 as MYCN transcriptional target: implications for neuroblastoma pathogenesis

Andrew Slack1, Guillermina Lozano, Jason M Shohet

  • 1Department of Pediatrics, Texas Children's Cancer Center, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA.

Cancer Letters
|June 2, 2005
PubMed

Insights

MYCN amplification drives aggressive neuroblastoma by increasing MDM2, a p53 regulator. Inhibiting MYCN reduces MDM2, stabilizing p53 and promoting apoptosis, suggesting MDM2 inhibition as a potential therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • MYCN amplification is a key driver of aggressive neuroblastoma with poor prognosis.
  • Understanding MYCN's downstream effectors is crucial for targeting this neuroblastoma subset.
  • MDM2, a negative regulator of the p53 tumor suppressor, is identified as a MYCN transcriptional target.

Purpose of the Study:

  • To investigate the role of MDM2 in MYCN-amplified neuroblastoma.
  • To explore the therapeutic potential of targeting MDM2 in neuroblastoma.

Main Methods:

  • Characterization of MDM2 as a transcriptional target of MYCN in neuroblastoma cell lines.
  • Targeted inhibition of MYCN to assess effects on MDM2 expression, p53 stabilization, and apoptosis.
  • Comparison with findings from MYCC-driven lymphoma mouse models.

Main Results:

  • MYCN directly regulates MDM2 expression in neuroblastoma.
  • Inhibition of MYCN leads to decreased MDM2 levels, p53 stabilization, and apoptosis induction.
  • MDM2's role in counterbalancing MYCN-stimulated apoptosis is suggested.

Conclusions:

  • MYCN-driven MDM2 expression may contribute to neuroblastoma's aggressive phenotype by suppressing p53 activity.
  • Targeting MDM2, pharmacologically or genetically, represents a promising therapeutic strategy for neuroblastoma.

More Related Videos

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor09:33

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor

Published on: August 25, 2023

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Master Transcription Regulators02:23

Master Transcription Regulators

Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a  complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic cells are...